A new study published in the New England Journal of Medicine suggests that the mammalian target of rapamycin complex (mTORC) affects vasculopathy in patients with antiphospholipid syndrome (APS).

A new study published in the New England Journal of Medicine suggests that the mammalian target of rapamycin complex (mTORC) affects vasculopathy in patients with antiphospholipid syndrome (APS).

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Design by Avery Nelson. Buy this photo. In a recent University of Michigan study, researchers ...